Pulmonology

Today, Eiger BioPharmaceuticals announced that results from the Phase 2 LIBERTY study demonstrated no improvement overall in its Phase 2 PAH treatment study, evaluating the effects of ubenimex.

A 1 mcg/m3 increase in average fine PM was associated 7.2% increase in asthma hospitalizations for patients aged 5 to 20 years old.

Boehringer Ingelheim announced the approval of a new indication for afatinib, as the U.S. FDA approved a supplemental NDA for the first-line treatment of patients with metastatic NSCLC whose tumors have non-resistant EGFR mutations.

The Antimicrobial Drugs Advisory Committee voted 12-3 against supporting whether Aradigm Corporation provided substantial evidence for the safety and efficacy of inhaled ciprofloxacin dispersion.

From January 2012 to July 2017, the FDA reportedly received 79 Medical Device Reports (MDRs) pertaining to pneumothorax events, including 16 deaths.

A new study looked at thousands of asthma patients in order to better understand the genetic associations of asthma.

The FDA recently approved the therapy after showing reduction in patients' polyp grade, and reduction in sense of nasal obstruction and congestion.

The trial featured schoolchildren with persistent asthma from an urban region.

The discovery fills a gap in lacking non-drug asthma therapies which health care providers can recommend to patients.

New research shows overweight preschoolers have more frequent asthma symptoms, but inhalers are still effective.

Researchers included smaller city, town, and rural residents for the study, noting they were populations previously excluded from US pollution-based studies.

Breastfeeding is associated with lower odds of developing asthma compared to formula than bottle feeding with expressed breast milk.

The label removal was backed by 4 clinical safety trials involving more than 40,000 patients.

A Lenox Hill Hospital dermatologist outlines the threats surrounding, and ideal therapies for, dermatological conditions brought on by pollution.

The first once-daily, triple-therapy inhaler drug was originally approved by the FDA in September.

The committee warns against the approval due to inconsistent data, concerns about drug resistance and lack of endpoints met.

The therapy showed up to 51% reduction in the annual exacerbation rate versus placebo.

The biologic agent has shown efficacy in reducing asthma exacerbations and improving patient quality of life.

Two consecutive CHEST studies showed combination therapy's expanding portfolio.

The FDA approved the inhaler treatment based on 2 Phase III-B studies running 6 months and 12 months, respectively, to compare the drug’s efficacy in COPD exacerbation care.

The approval marks the first FDA-approved treatment for pulmonary arterial hypertension.

COPD-related deaths increased 11.6% since 1990, and cases increased 44.2% to 174.5 million.

The FDA accepted an abbreviated new drug application for Sandoz ANDA.

CHASE 3 data support FDA approval of Symbicort in children 6 to >12 years.